.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
UBS
Chubb
Farmers Insurance
Moodys
Cipla
Mallinckrodt
Boehringer Ingelheim
Healthtrust
Queensland Health

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020394

« Back to Dashboard

NDA 020394 describes ATROVENT, which is a drug marketed by Boehringer Ingelheim and is included in five NDAs. It is available from three suppliers. There are three patents protecting this drug. Additional details are available on the ATROVENT profile page.

The generic ingredient in ATROVENT is ipratropium bromide. There are seven drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the ipratropium bromide profile page.

Summary for 020394

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Respiratory Tract Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 020394

Mechanism of ActionCholinergic Antagonists

Medical Subject Heading (MeSH) Categories for 020394

Suppliers and Packaging for NDA: 020394

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ATROVENT ipratropium bromide SPRAY, METERED;NASAL 020394 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0086 0597-0086-76 1 BOTTLE, PUMP in 1 CARTON (0597-0086-76) > 165 SPRAY, METERED in 1 BOTTLE, PUMP
ATROVENT ipratropium bromide SPRAY, METERED;NASAL 020394 NDA REMEDYREPACK INC. 52125-949 52125-949-15 15 SPRAY, METERED in 1 BOTTLE, PUMP (52125-949-15)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SPRAY, METERED;NASALStrength0.042MG/SPRAY
Approval Date:Oct 20, 1995TE:ABRLD:Yes

Expired Orange Book Patents for NDA: 020394

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer IngelheimATROVENTipratropium bromideSPRAY, METERED;NASAL020394-001Oct 20, 1995► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Cantor Fitzgerald
Healthtrust
Boehringer Ingelheim
Chubb
Johnson and Johnson
Cerilliant
McKinsey
Fish and Richardson
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot